Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo’s Semiannual Sales Up 6.2% Driven by Ranbaxy
November 1, 2012
- Japanese Pharmaceutical Industry Should Speak More Strongly in Favor of TPP: Paul King
November 1, 2012
- Bayer Announces Positive Results of PIII Trials of Riociguat in Patients with CTEPH, PAH
October 31, 2012
- Mochida, MTPC See Signs of Sales Growth for Lexapro after Lifting of Long-Term Prescription Ban
October 31, 2012
- All-Case Surveillance Lifted for Humira for Crohn’s Disease: Abbott Japan/Eisai
October 31, 2012
- Asahi Kasei Pharma Launches Global PIII Trial for Recomodulin
October 31, 2012
- Astellas Launches Quadruple Vaccine Quattrovac on October 31
October 31, 2012
- Takeda Files NDA in Japan for Cetilistat for Treatment of Obesity
October 31, 2012
- Mitsubishi Tanabe Reports Growth in 1st-Half Sales with Boost from Remicade, Telavic
October 31, 2012
- Kyowa Hakko Bio to Set Up New Plant in Thailand in Response to Rising Demand for Amino Acids
October 30, 2012
- Equity Participation in ViiV Hoped to Cover Patent Loss of Crestor: Shionogi Pres. Teshirogi
October 30, 2012
- Major Japanese Drug Makers Strengthen Vaccine Business, Eyeing Global Operations
October 30, 2012
- Shionogi to Take Part in GSK-Pfizer JV, Realigns Strategy in HIV Field
October 30, 2012
- DSP, Takeda Submit Application for Antipsychotic Lurasidone in Europe
October 30, 2012
- Nihon Chouzai to Make Choseido its Subsidiary to Strengthen Generic Products Supply Capacity
October 30, 2012
- Chugai to License SGLT-2 Inhibitor to Kowa, Sanofi
October 29, 2012
- Kyowa Kirin: Pharmaceutical Sales Up 8.4%, but Domestic Sales Down in January to September Period
October 29, 2012
- Nippon Chemiphar Revises 1st Half Business Forecast Upward, Full Year Forecast Unchanged
October 29, 2012
- MTPC to Launch Quadruple Vaccine TETRABIK on October 31 with 50 Vaccine Specialized MRs
October 29, 2012
- Janssen’s New MR Training System Aims to Produce “Consulting MRs”
October 29, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…